The landscape of drug and biological product development is currently undergoing a paradigm shift driven by the rapid maturation and integration of artificial intelligence (AI) and machine learning (ML). From AI-assisted regulatory submissions to broader artificial intelligence regulatory compliance, these technologies are now embedded across the pharmaceutical lifecycle.
Between 2016 and 2024, the FDA's Center for Drug Evaluation and Research (CDER) received more than 800 product submissions incorporating AI components, signaling that these technologies are no longer experimental novelties but integral components of the pharmaceutical life cycle. By early 2026, the number of AI-originated drug programs in clinical development surged to over 173, up from just 24 only a few years prior.
The message is clear: the FDA is no longer just observing these changes; they are actively shaping them with a new regulatory framework that prioritizes process oversight over just evaluating final outputs. Regulators are shifting toward the oversight of the full lifecycle of AI systems, with a focus on how models are designed, validated, deployed, and monitored.
Here is the technical and compliance "cut" of what these updates mean for the industry.